Core Viewpoint - AlphaTON Capital Corp is launching a privacy-first decentralized AI platform aimed at accelerating the development of treatments for rare cancers, starting with mesothelioma, leveraging its existing technology and partnerships [1][2][13]. Group 1: Platform Overview - The platform is designed to facilitate decentralized learning across institutions while maintaining patient data privacy, focusing initially on mesothelioma [2][10]. - It aims to provide actionable insights for clinical trials, including biomarker identification and trial design simulations, to enhance the development of therapies [2][11]. - The platform will utilize proprietary oncology datasets from AlphaTON's subsidiary, Cyncado Therapeutics, and will expand its data sources through partnerships [3][9]. Group 2: Strategic Implementation - A dedicated entity will be established to manage the platform, seeking independent financing while AlphaTON will focus on governance and infrastructure [4][12]. - The initiative is part of AlphaTON's broader Cocoon AI strategy, utilizing advanced GPU deployments to support the platform's computational needs [5][10]. - The platform will incorporate a Telegram-native collaboration layer to enhance scientific contributions and engagement in rare cancer research [8][11]. Group 3: Future Steps and Goals - Over the next 12 months, AlphaTON plans to finalize data agreements, launch the platform, and initiate pilot collaborations to produce early outputs for mesothelioma [11]. - As the platform develops, AlphaTON will explore structured approaches to advance individual therapeutic assets, including potential acquisitions and dedicated financing for clinical trials [12]. - The overarching goal is to create a scalable, clinically relevant platform that fosters collaboration and accelerates therapeutic advancements in rare cancers [13].